Owen Ang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Owen Ang has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Veronique Angeli
Immunology Translational Research Programme, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
3 shared publications Bien Keem Tan
Department of Plastic, Reconstructive and Aesthetic Surgery, Singapore General Hospital, Singapore, Singapore
2 shared publicationsChung Hwee Thiam
Immunology Translational Research Programme, Yong Loo Lin School of Medicine Department of Microbiology and Immunology, National University of Singapore, Singapore, Singapore
2 shared publicationsFederico Torta
Precision Medicine Translational Research Programme and Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
2 shared publicationsHwee Ying Lim
Immunology Translational Research Programme, Yong Loo Lin School of Medicine, Department of Microbiology and Immunology, National University of Singapore, Singapore, Singapore
2 shared publicationsJasmine Goh
Immunology Translational Research Programme, Yong Loo Lin School of Medicine Department of Microbiology and Immunology, National University of Singapore, Singapore, Singapore
2 shared publications
Latest Publications
- Open Access
- 12 June 2026
- Published by The Company of Biologists in preLights
Circadian Clock Programming of Anticipatory Antiviral Immunity Gates Enteric Virus Infection Susceptibility
- 12 June 2026
- Published by The Company of Biologists in preLights
Open AccessCircadian Clock Programming of Anticipatory Antiviral Immunity Gates Enteric Virus Infection Susceptibility
- Top Cited Papers
- 11 February 2026
- Published by Springer Nature in Nature
- Vol. 651 (8105) , 462-471
Targeting excessive cholesterol deposition alleviates secondary lymphoedema
Lymphoedema is a chronic debilitating disease caused by impaired lymphatic drainage and is characterized by tissue swelling, fat expansion, inflammation and fibrosis1,2. However, the exact mechanisms that drive lymphoedema are poorly understood. Although lymphatic vessels are known to transport cholesterol from peripheral tissues back to the systemic circulation3, the importance of impaired lymphatic drainage for cholesterol clearance in humans and its relevance to lymphoedema remain unknown. Here we show that lymphatic drainage insufficiency in human lymphoedema leads to excessive cholesterol accumulation in the lymphoedematous dermal tissue and around lymphatic vessels. Cholesterol deposition resulted in dermal adipose tissue remodelling, characterized by adipocyte hypertrophy and dysfunction, progressing to death and dermal fibrosis. Surgical intervention improved lymphatic drainage and reduced cholesterol deposition. Using two mouse models that reproduce features of human lymphoedema, we demonstrated that tissue swelling and dermal adipose tissue remodelling were ameliorated by the cholesterol-depleting agent cyclodextrin. Mechanistically, we demonstrated that cyclodextrin restored lymphatic drainage by promoting the regeneration of lymphatic vessels. This study unravels the role of impaired cholesterol clearance in driving lymphoedema and identifies tissue cholesterol as a promising therapeutic target for this currently incurable disease.
- 11 February 2026
- Published by Springer Nature in Nature
- Vol. 651 (8105) , 462-471
Top Cited PapersTargeting excessive cholesterol deposition alleviates secondary lymphoedema
Lymphoedema is a chronic debilitating disease caused by impaired lymphatic drainage and is characterized by tissue swelling, fat expansion, inflammation and fibrosis1,2. However, the exact mechanisms that drive lymphoedema are poorly understood. Although lymphatic vessels are known to transport cholesterol from peripheral tissues back to the systemic circulation3, the importance of impaired lymphatic drainage for cholesterol clearance in humans and its relevance to lymphoedema remain unknown. Here we show that lymphatic drainage insufficiency in human lymphoedema leads to excessive cholesterol accumulation in the lymphoedematous dermal tissue and around lymphatic vessels. Cholesterol deposition resulted in dermal adipose tissue remodelling, characterized by adipocyte hypertrophy and dysfunction, progressing to death and dermal fibrosis. Surgical intervention improved lymphatic drainage and reduced cholesterol deposition. Using two mouse models that reproduce features of human lymphoedema, we demonstrated that tissue swelling and dermal adipose tissue remodelling were ameliorated by the cholesterol-depleting agent cyclodextrin. Mechanistically, we demonstrated that cyclodextrin restored lymphatic drainage by promoting the regeneration of lymphatic vessels. This study unravels the role of impaired cholesterol clearance in driving lymphoedema and identifies tissue cholesterol as a promising therapeutic target for this currently incurable disease.
- Top Cited PapersOpen Access
- 4 September 2024
- Published by Springer Nature in Nature
- Vol. 634 (8033) , 457-465
Early intermittent hyperlipidaemia alters tissue macrophages to fuel atherosclerosis
Hyperlipidaemia is a major risk factor of atherosclerotic cardiovascular disease (ASCVD). Risk of cardiovascular events depends on cumulative lifetime exposure to low-density lipoprotein cholesterol (LDL-C) and, independently, on the time course of exposure to LDL-C, with early exposure being associated with a higher risk1. Furthermore, LDL-C fluctuations are associated with ASCVD outcomes2–4. However, the precise mechanisms behind this increased ASCVD risk are not understood. Here we find that early intermittent feeding of mice on a high-cholesterol Western-type diet (WD) accelerates atherosclerosis compared with late continuous exposure to the WD, despite similar cumulative circulating LDL-C levels. We find that early intermittent hyperlipidaemia alters the number and homeostatic phenotype of resident-like arterial macrophages. Macrophage genes with altered expression are enriched for genes linked to human ASCVD in genome-wide association studies. We show that LYVE1+ resident macrophages are atheroprotective, and identify biological pathways related to actin filament organization, of which alteration accelerates atherosclerosis. Using the Young Finns Study, we show that exposure to cholesterol early in life is significantly associated with the incidence and size of carotid atherosclerotic plaques in mid-adulthood. In summary, our results identify early intermittent exposure to cholesterol as a strong determinant of accelerated atherosclerosis, highlighting the importance of optimal control of hyperlipidaemia early in life, and providing insights into the underlying biological mechanisms. This knowledge will be essential to designing effective therapeutic strategies to combat ASCVD.
- 4 September 2024
- Published by Springer Nature in Nature
- Vol. 634 (8033) , 457-465
Top Cited PapersOpen AccessEarly intermittent hyperlipidaemia alters tissue macrophages to fuel atherosclerosis
Hyperlipidaemia is a major risk factor of atherosclerotic cardiovascular disease (ASCVD). Risk of cardiovascular events depends on cumulative lifetime exposure to low-density lipoprotein cholesterol (LDL-C) and, independently, on the time course of exposure to LDL-C, with early exposure being associated with a higher risk1. Furthermore, LDL-C fluctuations are associated with ASCVD outcomes2–4. However, the precise mechanisms behind this increased ASCVD risk are not understood. Here we find that early intermittent feeding of mice on a high-cholesterol Western-type diet (WD) accelerates atherosclerosis compared with late continuous exposure to the WD, despite similar cumulative circulating LDL-C levels. We find that early intermittent hyperlipidaemia alters the number and homeostatic phenotype of resident-like arterial macrophages. Macrophage genes with altered expression are enriched for genes linked to human ASCVD in genome-wide association studies. We show that LYVE1+ resident macrophages are atheroprotective, and identify biological pathways related to actin filament organization, of which alteration accelerates atherosclerosis. Using the Young Finns Study, we show that exposure to cholesterol early in life is significantly associated with the incidence and size of carotid atherosclerotic plaques in mid-adulthood. In summary, our results identify early intermittent exposure to cholesterol as a strong determinant of accelerated atherosclerosis, highlighting the importance of optimal control of hyperlipidaemia early in life, and providing insights into the underlying biological mechanisms. This knowledge will be essential to designing effective therapeutic strategies to combat ASCVD.
- Open Access
- 8 February 2024
- Published by Springer Nature in Research Square
Targeting excessive skin cholesterol deposition driven by lymphatic insufficiency alleviates secondary lymphedema
Lymphedema is a chronic debilitating disease caused by impaired lymphatic drainage and is characterized by tissue swelling, fat expansion, inflammation, and fibrosis1,2. However, the exact mechanisms driving lymphedema are poorly understood. Lymphatic vessels are known to transport lipids including cholesterol from peripheral tissues back to the blood circulation3 but the impact of impaired lymphatic drainage on cholesterol clearance in humans and its potential effects on tissue homeostasis are still unknown. Here, we show that lymphatic drainage insufficiency in human lymphedema leads to excessive cholesterol accumulation in subcutaneous tissue. Cholesterol deposition resulted in adipose tissue remodeling, progressing from adipocyte hypertrophy and dysfunction to death and tissue fibrosis. Surgical therapy, on the other hand reversed the process through improved lymphatic drainage, ultimately resulting in reduced cholesterol deposition. We established a mouse model that better reproduces the features of human lymphedema and demonstrated that tissue swelling, adipocyte hypertrophy and fibrosis were reversed by cholesterol depleting agents including high-density lipoprotein and cyclodextrin (CD) that improved lymphatic drainage upon increasing cholesterol clearance and/or solubility. Ex vivo, CD also efficiently removed cholesterol from human lymphedematous skin biopsy samples. Our study unravels the central role of impaired cholesterol clearance in driving lymphedema progression by promoting adipose tissue remodeling and identifies tissue cholesterol as a promising therapeutic target for this disease which is incurable. Our work highlights the importance of optimal lymphatic drainage to protect against excess cholesterol and its harmful effects. This concept is known in atherosclerosis and may apply to other human diseases including neurological disorders, liver, and metabolic diseases.
- 8 February 2024
- Published by Springer Nature in Research Square
Open AccessTargeting excessive skin cholesterol deposition driven by lymphatic insufficiency alleviates secondary lymphedema
Lymphedema is a chronic debilitating disease caused by impaired lymphatic drainage and is characterized by tissue swelling, fat expansion, inflammation, and fibrosis1,2. However, the exact mechanisms driving lymphedema are poorly understood. Lymphatic vessels are known to transport lipids including cholesterol from peripheral tissues back to the blood circulation3 but the impact of impaired lymphatic drainage on cholesterol clearance in humans and its potential effects on tissue homeostasis are still unknown. Here, we show that lymphatic drainage insufficiency in human lymphedema leads to excessive cholesterol accumulation in subcutaneous tissue. Cholesterol deposition resulted in adipose tissue remodeling, progressing from adipocyte hypertrophy and dysfunction to death and tissue fibrosis. Surgical therapy, on the other hand reversed the process through improved lymphatic drainage, ultimately resulting in reduced cholesterol deposition. We established a mouse model that better reproduces the features of human lymphedema and demonstrated that tissue swelling, adipocyte hypertrophy and fibrosis were reversed by cholesterol depleting agents including high-density lipoprotein and cyclodextrin (CD) that improved lymphatic drainage upon increasing cholesterol clearance and/or solubility. Ex vivo, CD also efficiently removed cholesterol from human lymphedematous skin biopsy samples. Our study unravels the central role of impaired cholesterol clearance in driving lymphedema progression by promoting adipose tissue remodeling and identifies tissue cholesterol as a promising therapeutic target for this disease which is incurable. Our work highlights the importance of optimal lymphatic drainage to protect against excess cholesterol and its harmful effects. This concept is known in atherosclerosis and may apply to other human diseases including neurological disorders, liver, and metabolic diseases.